

Hybrigenics obtains patent protection for an improved chemical synthesis of inecalcitol

Paris, February 27, 2011 - Hybrigenics SA (ALHYG), a bio-pharmaceutical company listed on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of new treatments against proliferative diseases announces today that it has received from the European Patent Office the official notification of its intent to grant Hybrigenics' patent on the crucial "14-epimerization" step in the synthesis of inecalcitol.

Filed in 2010 (cf Hybrigenics' press release of March 11, 2010), this patent application has been approved under an accelerated procedure in just 2 years, and will provide additional patent protection to inecalcitol until 2030. Furthermore, this improved chemical process increases the yield of inecalcitol synthesis and lowers the manufacturing costs of future industrial batches.

This is the second patent granted which renews and prolongs the intellectual property of inecalcitol, after the patent protecting its therapeutic use at high doses (cf Hybrigenics' press release of January 24, 2011). A third patent application is pending covering innovative formulations of inecalcitol: tablets, new generation of soft gelatin capsules and drinking solutions (cf Hybrigenics' press release of November 2nd, 2010).

Oral inecalcitol is currently being tested at 4 mg per day for treatment of moderate-to-severe psoriasis in a placebo-controlled double-blind clinical trial. The results of this Phase II study are expected in June 2012. Oral inecalcitol has previously shown excellent tolerance and a strong presumption of efficacy in a phase IIa dose-finding clinical study in prostate cancer in combination with Taxotere®. An application to test oral inecalcitol in chronic lymphocytic leukemia patients is currently under review by the new French National Agency for Drug Safety (cf Hybrigenics' press release of January 19, 2012).

"Our strategy is to optimize all components of inecalcitol development and to build several fences of industrial protection around it. Our fast and efficient patenting process has secured Hybrigenics' intellectual property of inecalcitol up to 2030," said Rémi Delansorne, Hybrigenics' CEO.

About Hybrigenics

Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.

Hybrigenics' current development program is based on inecalcitol, a vitamin D receptor agonist, for the first-line treatment of metastatic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Inecalcitol is also being developed to treat moderate-to-severe psoriasis by oral administration.

HYBRIGENICS

Press Release

Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.

Hybrigenics Services SAS, a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform

HYBRIGENICS is listed on the Alternext by NYSE Euronext Paris

ISIN: FR0004153930

Ticker: ALHYG



Hybrigenics

Rémi Delansorne

CEO

Tel.: +33 (0)1 58 10 38 00

investors@hybrigenics.com

NewCap.

Financial communication

Axelle Vuillermet / Pierre Laurent

Tel.: +33 (0)1 44 71 94 94

hybrigenics@newcap.fr